Imiquimod-induced vitiligo after treatment of nodular basal cell carcinoma.

An 84-year-old male presented with recurrent nodular infiltrative basal cell carcinoma on the left shoulder. The patient was treated with curettage followed by the application of topical imiquimod 5% cream five times a week. The patient discontinued imiquimod after a total of 18 applications because of local inflammation.

A 36-month clinical experience of the effectiveness of curettage and imiquimod 5% cream in the treatment of basal cell carcinoma.

Background: Electrodesiccation and curettage is commonly used for the treatment of basal cell carcinomas (BCCs). Does the addition of imiquimod 5% cream improve clearance rates and cosmetic outcomes?

Objective: To evaluate a 3-year clinical experience of the effectiveness of curettage combined with imiquimod cream in the treatment of BCC.

Methods: Patients were enrolled into the study in the first 10 months of 2003.

Topical imiquimod therapy for basal and squamous cell carcinomas: a clinical experience.

Basal cell carcinomas (BCCs) and cutaneous squamous cell carcinomas (SCCs) are the most common malignancies in humans. Together, they constitute approximately 95% of nonmelanoma skin cancers (NMSCs). Surgical excision remains the mainstay of therapy of low-risk NMSC, though Mohs micrographic surgery is the gold standard for high-risk NMSC.

Localized melanosis in an immunocompromised patient with local metastatic melanoma.

Background: Melanosis is a rare, but well recognized late complication of some cases of metastatic melanoma. The precise pathogenesis is unclear. Most described cases report diffuse metastases and diffuse melanosis.